Have a feature idea you'd love to see implemented?
Let us know!
IBIO iBio Inc
Price (delayed)
$2.45
Market cap
$22.42M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.61
Enterprise value
$15.59M
iBio is a global leader in plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and
Highlights
The EPS has soared by 94% YoY and by 29% from the previous quarter
IBIO's debt has plunged by 74% YoY and by 8% from the previous quarter
The company's equity rose by 34% YoY but it fell by 17% QoQ
iBio's revenue has decreased by 22% QoQ
iBio's gross profit has decreased by 22% QoQ
Key stats
What are the main financial stats of IBIO
Market
Valuations
Earnings
Shares outstanding
9.15M
Market cap
$22.42M
Enterprise value
$15.59M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.19
Price to sales (P/S)
120.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
89.06
Revenue
$175,000
EBIT
-$22.95M
EBITDA
-$21.74M
Free cash flow
-$16.07M
Per share
Balance sheet
Liquidity
EPS
-$4.61
Free cash flow per share
-$1.86
Book value per share
$2.06
Revenue per share
$0.02
TBVPS
$2.22
Total assets
$24.52M
Total liabilities
$6.76M
Debt
$4.43M
Equity
$17.75M
Working capital
$8.24M
Debt to equity
0.25
Current ratio
3.37
Quick ratio
3.25
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
-12,421.1%
Gross margin
100%
Net margin
-13,228.6%
Operating margin
-8,935.4%
Return on assets
-67.4%
Return on equity
-126.6%
Return on invested capital
-124.1%
Return on capital employed
-109%
Return on sales
-13,112.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IBIO stock price
How has the iBio stock price performed over time
Intraday
11.87%
1 week
13.95%
1 month
-20.71%
1 year
-54.03%
YTD
78.83%
QTD
10.36%
Financial performance
How have iBio's revenue and profit performed over time
Revenue
$175,000
Gross profit
$175,000
Operating income
-$15.64M
Net income
-$23.15M
Gross margin
100%
Net margin
-13,228.6%
IBIO's net margin has soared by 87% YoY but it is down by 20% from the previous quarter
The company's operating margin has surged by 83% YoY but it fell by 21% QoQ
The company's net income has surged by 56% YoY and by 7% QoQ
The operating income has increased by 42% year-on-year and by 6% since the previous quarter
Growth
What is iBio's growth rate over time
Valuation
What is iBio stock price valuation
P/E
N/A
P/B
1.19
P/S
120.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
89.06
The EPS has soared by 94% YoY and by 29% from the previous quarter
IBIO's price to book (P/B) is 70% higher than its last 4 quarters average of 0.7 but 52% lower than its 5-year quarterly average of 2.5
The company's equity rose by 34% YoY but it fell by 17% QoQ
IBIO's price to sales (P/S) is 37% more than its 5-year quarterly average of 88.0 but 2.9% less than its last 4 quarters average of 124.5
iBio's revenue has decreased by 22% QoQ
Efficiency
How efficient is iBio business performance
The ROS has soared by 88% YoY but it has contracted by 19% from the previous quarter
iBio's return on equity has surged by 61% YoY and by 13% QoQ
iBio's return on assets has increased by 44% YoY
The ROIC has grown by 36% YoY but it has contracted by 12% from the previous quarter
Dividends
What is IBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IBIO.
Financial health
How did iBio financials performed over time
The company's total liabilities has shrunk by 72% YoY and by 9% QoQ
iBio's total assets has decreased by 35% YoY and by 15% from the previous quarter
IBIO's debt is 75% less than its equity
The company's debt to equity has shrunk by 80% YoY but it rose by 9% QoQ
IBIO's debt has plunged by 74% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.